Sarepta Therapeutics, Inc. (SRPT) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1160298,
    "name": "Sarepta Therapeutics, Inc.",
    "stock_name": "Sarepta Therapeutics, Inc.",
    "full_name": "Sarepta Therapeutics, Inc.",
    "name_url": "stocks-analysis/sarepta-therapeutics-inc",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "22.82",
    "chg": 2.35,
    "chgp": "11.48%",
    "dir": 1,
    "prev_price": "20.47",
    "mcapval": "1,719.76",
    "mcap": "Small Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2305,
    "indexname": "S&P 500",
    "isin": "US8036071004",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "6.79 M",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/sarepta-therapeutics-inc-1160298-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Sarepta Therapeutics Stock Soars 8.75%, Hits Intraday High of $19.34",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/sarepta-therapeutics-stock-soars-875-hits-intraday-high-of-1934-3585860",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/SareptaTherapeu_priceRelatedfactors_3585860.png",
        "date": "2025-10-01 16:10:51",
        "description": "Sarepta Therapeutics, Inc. has seen a significant increase in its stock price today, contrasting with the modest rise of the S&P 500. Despite a recent uptick, the company faces long-term challenges, including a substantial decline in profitability and a high debt-equity ratio, while maintaining strong institutional ownership."
      },
      {
        "title": "Sarepta Therapeutics Hits Day High with Strong 7% Intraday Surge",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/sarepta-therapeutics-hits-day-high-with-strong-7-intraday-surge-3559168",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/9/SareptaTherapeu_priceRelatedfactors_3559168.png",
        "date": "2025-09-23 15:03:28",
        "description": "Sarepta Therapeutics, Inc. experienced a notable stock price increase on September 22, 2025, reaching an intraday high. However, the company has faced significant challenges, including an 84.79% decline over the past year and a substantial net loss, raising concerns about its financial stability and market position."
      },
      {
        "title": "Is Sarepta Therapeutics, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-sarepta-therapeutics-inc-technically-bullish-or-bearish-3545855",
        "imagepath": "",
        "date": "2025-09-20 19:20:13",
        "description": "As of 12 August 2025, the technical trend for Sarepta Therapeutics, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by a combination of indicators. The MACD shows a mildly bullish signal on the weekly timeframe but is bearish on the monthly. The RSI is bullish monthly but shows no signal weekly. Moving averages indicate a mildly bearish trend on the daily timeframe. Additionally, Bollinger Bands and KST are both mildly bearish on the weekly and monthly timeframes, while OBV is mildly bullish monthly but mildly bearish weekly. \n\nIn terms of performance, Sarepta has significantly underperformed compared to the S&P 500 across multiple periods, with a year-to-date return of -84.77% versus the S&P 500's 12.22%...."
      },
      {
        "title": "Is Sarepta Therapeutics, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-sarepta-therapeutics-inc-overvalued-or-undervalued-3542525",
        "imagepath": "",
        "date": "2025-09-20 17:55:06",
        "description": "As of 6 May 2025, the valuation grade for Sarepta Therapeutics, Inc. has moved from attractive to risky, indicating a significant deterioration in its valuation outlook. The company is currently overvalued, as evidenced by its Price to Book Value of 3.70 and an EV to Sales ratio of 2.17, both of which suggest that the stock is trading at a premium compared to its underlying assets and revenue generation capabilities. Additionally, the negative EV to EBITDA of -77.97 highlights the challenges the company faces in generating positive earnings before interest, taxes, depreciation, and amortization.\n\nIn comparison to its peers, Sarepta's valuation metrics are concerning; for instance, Viatris, Inc. has a P/E ratio of 44.86, while Walgreens Boots Alliance, Inc. shows a P/E of -14.12, both indicating a more favorable valuation relative to their earnings. Furthermore, Sarepta's recent stock performance has been di..."
      },
      {
        "title": "Sarepta Therapeutics Hits Day High with 8.62% Surge in Intraday Trading",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/sarepta-therapeutics-hits-day-high-with-862-surge-in-intraday-trading-3537252",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/9/SareptaTherapeu_priceRelatedfactors_3537252.png",
        "date": "2025-09-19 13:35:35",
        "description": "Sarepta Therapeutics, Inc. saw a significant stock price increase on September 18, 2025, reaching an intraday high. However, the company has faced substantial declines over the past year and year-to-date, alongside troubling financial metrics, including a negative net profit and high debt-equity ratio, raising concerns about its market position."
      }
    ],
    "total": 10,
    "sid": "1160298",
    "stock_news_url": "https://www.marketsmojo.com/news/sarepta-therapeutics-inc-1160298"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Sarepta Therapeutics Stock Soars 8.75%, Hits Intraday High of $19.34

2025-10-01 16:10:51

Sarepta Therapeutics, Inc. has seen a significant increase in its stock price today, contrasting with the modest rise of the S&P 500. Despite a recent uptick, the company faces long-term challenges, including a substantial decline in profitability and a high debt-equity ratio, while maintaining strong institutional ownership.

Sarepta Therapeutics Hits Day High with Strong 7% Intraday Surge

2025-09-23 15:03:28

Sarepta Therapeutics, Inc. experienced a notable stock price increase on September 22, 2025, reaching an intraday high. However, the company has faced significant challenges, including an 84.79% decline over the past year and a substantial net loss, raising concerns about its financial stability and market position.

Is Sarepta Therapeutics, Inc. technically bullish or bearish?

2025-09-20 19:20:13

As of 12 August 2025, the technical trend for Sarepta Therapeutics, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by a combination of indicators. The MACD shows a mildly bullish signal on the weekly timeframe but is bearish on the monthly. The RSI is bullish monthly but shows no signal weekly. Moving averages indicate a mildly bearish trend on the daily timeframe. Additionally, Bollinger Bands and KST are both mildly bearish on the weekly and monthly timeframes, while OBV is mildly bullish monthly but mildly bearish weekly. In terms of performance, Sarepta has significantly underperformed compared to the S&P 500 across multiple periods, with a year-to-date return of -84.77% versus the S&P 500's 12.22%....

Is Sarepta Therapeutics, Inc. overvalued or undervalued?

2025-09-20 17:55:06

As of 6 May 2025, the valuation grade for Sarepta Therapeutics, Inc. has moved from attractive to risky, indicating a significant deterioration in its valuation outlook. The company is currently overvalued, as evidenced by its Price to Book Value of 3.70 and an EV to Sales ratio of 2.17, both of which suggest that the stock is trading at a premium compared to its underlying assets and revenue generation capabilities. Additionally, the negative EV to EBITDA of -77.97 highlights the challenges the company faces in generating positive earnings before interest, taxes, depreciation, and amortization. In comparison to its peers, Sarepta's valuation metrics are concerning; for instance, Viatris, Inc. has a P/E ratio of 44.86, while Walgreens Boots Alliance, Inc. shows a P/E of -14.12, both indicating a more favorable valuation relative to their earnings. Furthermore, Sarepta's recent stock performance has been di...

Sarepta Therapeutics Hits Day High with 8.62% Surge in Intraday Trading

2025-09-19 13:35:35

Sarepta Therapeutics, Inc. saw a significant stock price increase on September 18, 2025, reaching an intraday high. However, the company has faced substantial declines over the past year and year-to-date, alongside troubling financial metrics, including a negative net profit and high debt-equity ratio, raising concerns about its market position.

View All News